- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
Stuart A. Aaronson, MD
Jack and Jane B. Aron Professor
Founding Chair Emeritus
Department of Oncological Sciences
Mount Sinai, Icahn School of Medicine
New York, New York
- Working to improve treatment of aggressive breast cancers.
- Laboratory studies are ongoing to identify new drug targets in triple negative and inflammatory breast cancers.
- These studies are providing new insights into potential new diagnostics and therapies for breast cancer patients.
Discoveries made in the laboratory are key to advancing new treatments for patients, and new treatments are urgently needed for patients with triple negative and inflammatory breast cancers. Dr. Aaronson is conducting a series of laboratory studies to identify new targets and drugs for patients with these aggressive breast cancers.
Full Research Summary
Dr. Aaronson's work is focused on identifying biomarkers that may lead to new therapies in several types of aggressive breast cancers. Work in his laboratory led to the discovery that the HER2 gene is the driving factor in about 30 percent of breast cancers, cancers that are now treatable with targeted anti-HER2 therapies. His current BCRF project is focused on a protein called Wnt and its role in triple negative breast cancer.
Dr. Aaronson previously showed that triple negative breast tumor cells with high Wnt activity are more invasive and survive better than those that do not have high Wnt activity. He is leading ongoing efforts to develop drugs to block the Wnt pathway and stop the growth of triple negative tumor cells. In previous work his team showed that drugs that block Wnt also hit another target called Hippo, which contributes to some breast cancers. Inhibition of Wnt and Hippo significantly inhibited the growth of such breast tumors.
Over the last year, his group showed that certain mutations in the p53 tumor suppressor gene not only inactivate p53 but also cause deregulation of Hippo pathway resulting in aggressive tumor growth. They have identified two classes of small molecule inhibitors that specifically antagonizes the growth of such breast tumors. They will extend these findings to provide additional insights into potential new diagnostics and therapies for breast cancer patients.
Another area of interest of Dr. Aaronson’s laboratory is inflammatory breast cancer, a rare but very aggressive form of the breast cancer. His group has been actively pursuing possible therapeutic strategies to specifically target inflammatory breast cancer, while continuing to explore other signaling pathways that contribute to some breast cancers.
Collectively, Dr. Aaronson's research has led to important discoveries in triple negative, HER2-positive, and inflammatory breast cancers that will lead to better diagnostics and treatments for these diseases.
Dr. Aaronson’s research is focused on discovery and functions of cancer genes. At the NCI as Chief, Laboratory of Cellular and Molecular Biology, he identified the first normal function of a cancer gene as that of a growth factor, PDGF, and cloned erbB2 (also designated HER2/neu), a novel growth factor receptor gene he detected as amplified in a human breast carcinoma. This discovery and his subsequent investigations paved the way for diagnostic tests to identify breast cancer patients, who benefit from erbB2-targeted therapies. He discovered KGF (FGF7), a growth factor with novel epithelial cell specificity, now FDA approved for use in the treatment of mucositis, a debilitating side effect of many cancer therapies. His discoveries of other critical components in growth factor signaling pathways and their implications in cancer including erbB3, the alpha PDGF receptor and HGF as the ligand for MET have also led to pre-clinical and clinical development of new agents targeting these molecules in tumors. Dr. Aaronson joined Mount Sinai in 1993 and built a cancer research department, which has grown to more than 25 faculty members. As Founding Chair Emeritus, his research continues to explore new therapeutic targets in breast and other cancers with the goal of translating these advances to patients. Dr. Aaronson is an internationally recognized physician scientist with over 500 publications and over 50 patents. He has trained dozens of investigators, who have gone on to establish careers in major academic centers and biotech/pharma in this country and abroad.